Categories : Anti-Infectives
Product Packaging : 10 / 30 tablets
Product Composition : 90 mg + 400 mg
Send MessageGenliva Wellness LLP manufactures Ledipasvir + Sofosbuvir Tablets for chronic hepatitis C virus infection requiring direct-acting antiviral therapy. The formulation is widely incorporated into HCV treatment regimens targeting viral suppression and long-term liver health management.
Ledipasvir inhibits the NS5A protein involved in hepatitis C viral replication, while Sofosbuvir acts on the NS5B polymerase enzyme responsible for viral RNA synthesis. This antiviral combination is frequently utilized in genotype-specific hepatitis C treatment protocols across institutional and outpatient healthcare systems.
Genliva Wellness LLP specializes in antiviral pharmaceutical manufacturing in Gujarat supplying hepatitis treatment formulations for government healthcare initiatives, institutional procurement agencies, pharmaceutical distributors, and regulated international export markets.
Ledipasvir + Sofosbuvir Tablets are formulated for direct-acting antiviral hepatitis C therapy.
This formulation is prescribed in hepatitis C antiviral treatment management.
Ledipasvir + Sofosbuvir Tablets deliver direct-acting antiviral therapy for HCV management.
